Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmutepSTU:YP1A -6.72%30 EV-to-EBITDA is 0.11 as of Sep. 22, 2026. GuruFocus rates STU:YP1A with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 430 Biotechnology companies, Immutep ranks better than 92.79% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Immutep's enterprise value is €-5.09 Mil.
Immutep's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-44.64 Mil. Therefore, Immutep's EV-to-EBITDA for today is 0.11.
The historical rank and industry rank for Immutep's EV-to-EBITDA or its related term are showing as below:
STU:YP1A'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.19 Med: 0 Max: 0.27
Current: 0.27
During the past 13 years, the highest EV-to-EBITDA of Immutep was 0.27. The lowest was -0.19. And the median was 0.00.
STU:YP1A's EV-to-EBITDA is ranked better than 92.79% of 430
companies
in the Biotechnology industry
Industry Median: 13.015
vs STU:YP1A: 0.27
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-09-22), Immutep's stock price is €0.248.
Immutep's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.312. Therefore, Immutep's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Immutep's share price for today is €0.248.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Immutep's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.312.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Immutep's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:YP1A vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Immutep's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immutep EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immutep's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Immutep's EV-to-EBITDA falls into.
Immutep's current Enterprise Value is €-5.09 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Immutep's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-44.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immutep (STU:YP1A) has a EV-to-EBITDA of 0.11 as of Sep. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Immutep. According to the industry distribution chart, Immutep ranks #31 out of 430 companies in the Biotechnology industry, placing it in the top 7.2%.
Is Immutep's EV-to-EBITDA too high?
Immutep's current EV-to-EBITDA is 0.11. The Biotechnology industry median EV-to-EBITDA is 13.02. Immutep's value of 0.11 is 99.2% below this industry median. Based on the distribution chart, Immutep ranks #31 out of 430 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Immutep has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Immutep's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immutep ranks #31 out of 430 companies for EV-to-EBITDA. This places Immutep in the top 7% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.02. Immutep's value of 0.11 is 99.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.02, based on 430 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immutep's current EV-to-EBITDA of 0.11 is 99.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Immutep. For the Biotechnology industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immutep's current EV-to-EBITDA is 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immutep stock overvalued right now?
Immutep (STU:YP1A) has a current EV-to-EBITDA of 0.11. The current EV-to-EBITDA is 0.11 and 99.2% below the Biotechnology industry median of 13.02. Immutep's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Immutep (STU:YP1A), the current EV-to-EBITDA is 0.11 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
30GF Score
Get the complete analysis for STU:YP1A
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:YP1A has been successfully added to your 
